Biotechnology is entering a new era, with advances in artificial intelligence, cell therapy, and immune engineering creating new possibilities for treating complex diseases. Behind these developments are entrepreneurs and executives working to translate scientific discoveries into therapies and technologies that can make a meaningful difference in patients’ lives.
From AI-driven drug discovery to next-generation immunotherapies, these five leaders are helping shape how the industry approaches some of medicine’s most difficult challenges. Their work reflects a broader shift toward more targeted, data-driven, and potentially transformative approaches to drug development and treatment.
Evan Feinberg — Founder and CEO of Genesis Molecular AI
Evan Feinberg is the founder and CEO of Genesis Molecular AI, a biotechnology company focused on using artificial intelligence to accelerate the discovery and development of new medicines. His work sits at the intersection of computational biology, machine learning, and drug development, where AI has the potential to help researchers better understand complex biological systems and identify promising therapeutic candidates.
Feinberg’s leadership reflects a growing effort to make drug discovery more predictive and efficient. By applying AI to molecular design and biological research, Genesis Molecular AI aims to help bridge the gap between scientific insights and potential treatments. As pharmaceutical companies increasingly explore AI-powered research, leaders building at this intersection are helping define how emerging technologies could change the process of bringing new medicines to patients.
Lynn Seely — President and CEO of Lyell Immunopharma
Lynn Seely leads Lyell Immunopharma, a biotechnology company developing next-generation cell therapies for cancer. As president and CEO, she oversees the company’s efforts to advance engineered T-cell therapies designed to address limitations that can prevent the immune system from effectively attacking tumors. Her leadership brings an executive perspective to one of biotechnology’s most complex fields, where scientific innovation must be matched with rigorous clinical development.
Cell therapy has emerged as an important area of cancer research, but challenges such as T-cell exhaustion and limited persistence can affect treatment effectiveness. Lyell’s research has focused on engineering T cells to improve their function and durability, with the broader goal of developing more effective treatments for patients with cancer. Seely’s role involves guiding the company’s scientific and clinical priorities while navigating the demanding process of translating experimental approaches into potential therapies.
Ivana Djuretic — Founder and CEO of Asher Bio
Ivana Djuretic is the founder and CEO of Asher Bio, a biotechnology company developing precision immunotherapies for cancer and other diseases. Drawing on her background in immunology and drug discovery, she leads the company’s efforts to engineer medicines that selectively activate beneficial immune cells while minimizing unwanted effects. Before founding Asher Bio, Djuretic held scientific leadership roles at Pfizer and worked on immunotherapy programs at Celgene and Tempero Pharmaceuticals.
A central focus of Asher Bio’s approach is improving the selectivity of cytokine-based therapies, which can stimulate immune responses but also affect cell populations that may undermine treatment or cause toxicity. The company’s cis-targeting platform is designed to direct therapeutic activity toward specific immune cell types. Under Djuretic’s leadership, Asher Bio is working to translate advances in immune engineering into treatments that could improve outcomes for patients with cancer and potentially other challenging diseases.
.Diana Abdueva — Co-founder and CEO of Aqtual
Diana Abdueva is the co-founder and CEO of Aqtual, a biotechnology company developing a functional liquid biopsy platform designed to provide deeper insights into disease biology. With expertise in computational biology and genomics, Abdueva is helping advance methods that analyze cell-free DNA in blood to reveal information about biological activity. Rather than focusing solely on conventional genetic mutations, Aqtual examines signals associated with active chromatin to help researchers understand how disease-related processes are unfolding in the body.
The company’s approach aims to expand the possibilities of blood-based testing across oncology, autoimmune conditions, and other chronic diseases. By investigating the regulatory signals carried in cell-free DNA, Aqtual seeks to help researchers and clinicians better characterize disease, stratify patients, and evaluate treatment responses. Abdueva’s work illustrates how advances in genomics and computational analysis could make liquid biopsy a more informative tool for precision medicine, potentially supporting earlier insights and more individualized treatment decisions.
Li-Fen Lee — Founder and CEO of Apeximmune Therapeutics
Li-Fen Lee is identified as the founder and CEO of Apeximmune Therapeutics, a biotechnology company focused on developing therapeutic antibodies and biologics that harness the immune system to treat cancer and autoimmune diseases. The company’s research centers on discovering and validating immune-modulating targets and pathways, then using those insights to develop potential drug candidates. This work addresses a central challenge in immunotherapy: understanding how to regulate immune activity to achieve a therapeutic benefit without triggering unwanted responses.
Apeximmune’s approach spans both enhancing and suppressing immune function, depending on the disease and the biological pathways involved. In cancer, therapies may seek to strengthen immune responses against tumors, while autoimmune conditions can require strategies that reduce harmful immune activity. By focusing on target discovery, biological validation, and therapeutic development, the company aims to identify new ways to address diseases that remain difficult to treat. Its work reflects the broader biotechnology industry’s pursuit of more precise medicines grounded in a deeper understanding of the immune system.
Building What Comes Next in Biotechnology
The future of medicine depends on more than scientific breakthroughs alone. It requires leaders who can connect discoveries in molecular biology, genomics, artificial intelligence, and immunology with the clinical research and development needed to turn promising ideas into treatments.
Across drug discovery, cell therapy, immune engineering, and precision diagnostics, these companies represent different approaches to a shared objective: making medicine more targeted, more informative, and more effective. Their progress will depend on continued scientific validation, clinical evidence, and the ability to translate innovation into meaningful benefits for patients.
